Serum uric acid is associated with increased risk of idiopathic venous thromboembolism in high HDL-C population: A case-control study

Abstract Background: Previous studies have shown that serum uric acid (SUA) and dyslipidemia are risk factors for stroke. However, it is not clear that whether dyslipidemia could modify the association between SUA and hemorrhagic stroke.Methods: We conducted a nested case-control study from “H-type Hypertension and Stroke Prevention and Control Project (HSPCP)” in China. A total of 355 first hemorrhagic stroke cases and 355 controls matched for age (± 1 years), sex and study site were included in the final data analysis. Logistic regression analysis were performed to assess the association between SUA and first hemorrhagic stroke.Results: In matched analysis, the risk of hemorrhagic stroke was associated with the increased SUA levels (OR:1.13, 95% CI:0.98 to 1.30). However, multiple regression analyses showed that per 1 mg/dL in SUA was associated with a 16% decreased risk of hemorrhagic stroke among participants without dyslipidemia and associated with a 28% increased risk of hemorrhagic stroke among dyslipidemia participants [without dyslipidemia: odds ratio (OR) = 0.84, 95% CI 0.65 to 1.09, with dyslipidemia: OR = 1.28, 95% CI 1.10 to 1.48; P Interaction ＜0.001]. The results of the subgroup analysis were consistent with the main results.Conclusions: Elevated SUA was associated with increased risk of hemorrhagic stroke especially among participants with dyslipidemia. These findings suggest that we need to focus on SUA levels especially among participants with dyslipidemia.

Download Full-text

Study of Correlation of Serum Uric Acid Level and Cardiovascular Diseases and Its Severity: An Observational Case–Control Study

Journal of Mahatma Gandhi University of Medical Sciences and Technology ◽

10.5005/jp-journals-10057-0157 ◽

2021 ◽

Vol 6 (1) ◽

pp. 15-16

Author(s):

Mukesh Jain ◽

Puneet Rijhwani ◽

Arpit Pareek ◽

Dharam P Bansal ◽

Ram K Jat ◽

...

Keyword(s):

Uric Acid ◽

Cardiovascular Diseases ◽

Serum Uric Acid ◽

Uric Acid Level ◽

Acid Level ◽

Case Control Study ◽

Serum Uric Acid Level ◽

Case Control ◽

Control Study

Download Full-text

Serum Uric Acid Levels in Relation to Atrial Fibrillation: A Case-Control Study

Medical Science Monitor ◽

10.12659/msm.934007 ◽

2021 ◽

Vol 28 ◽

Author(s):

Xia Zhong ◽

Huachen Jiao ◽

Dongsheng Zhao ◽

Jing Teng

Keyword(s):

Atrial Fibrillation ◽

Uric Acid ◽

Serum Uric Acid ◽

Case Control Study ◽

Case Control ◽

Control Study

Download Full-text

Association between Statin and Fibrate Use and Venous Thromboembolism: A Case-Control Study.

Blood ◽

10.1182/blood.v104.11.2594.2594 ◽

2004 ◽

Vol 104 (11) ◽

pp. 2594-2594

Author(s):

Karine Lacut ◽

Gregoire Le Gal ◽

Emmanuel Oger ◽

Dominique Mottier

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Protective Effect ◽

Case Control Study ◽

Case Control ◽

Increased Risk ◽

Venous Thromboembolic ◽

The Difference ◽

Control Study ◽

Statin Use

Abstract Background: Previous studies of selected patients have suggested a reduction in the risk of venous thromboembolism (VTE) with the use of statins, and no effect of fibrates. Objective: To evaluate the influence of statin and fibrate use on the risk of venous thromboembolic events. Design: Case-control study (EDITH) designed to investigate genetic and environmental risk factors of VTE. Setting: Brest University Hospital. Participants: 857 patients consecutively hospitalized for a documented venous thromboembolic event were included between May 2000 and May 2004. Controls were matched on age, sex and the main risk factors of VTE (cancer, surgery, pregnancy…). Results: The mean age of patients was 67.7 year. No significant difference was found between cases and controls concerning the main characteristics, except for smocking and body mass index. Controls had more often previous vascular events (coronary heart disease, stroke or arteriopathy of the lower limbs) than cases but the difference was no significant. Statin use was associated with a significant decreased risk of VTE (odds ratio (OR) = 0.58; 95% confidence interval (CI), 0.41–0.82), whereas fibrate use was associated with a significant increased risk of VTE (OR = 1.60; 95% CI, 1.09–2.34). After adjustment on the main confounding factors including aspirin use and cardiovascular disease, these associations remained significant. Among pleiotropic effects of statins, some antithrombotic mechanisms could be proposed to explain their possible protective effect. Concerning the possible negative effect of fibrates, some authors found that the most prescribed fibrates, but not statins, caused hyperhomocysteinemia. In our study, analyses of homocysteinemia are ongoing. Conclusion: In this case-control study of hospitalized patients, statin use was associated with a significant decreased risk of VTE, whereas fibrate use was associated with a significant increased risk. Homocysteinemia may be involved in the difference between the effects of these two categories of lipid-lowering drugs on VTE. Because our study was observational, the protective effect of statins as regards the risk of VTE remains questionable and further prospective studies are needed.

Download Full-text

Association between Neuroleptics and Venous Thromboembolism: A Case-Control Study.

Blood ◽

10.1182/blood.v104.11.2601.2601 ◽

2004 ◽

Vol 104 (11) ◽

pp. 2601-2601

Author(s):

Karine Lacut ◽

Gregoire Le Gal ◽

Emmanuel Oger ◽

Dominique Mottier

Keyword(s):

Risk Factors ◽

Venous Thromboembolism ◽

Antipsychotic Drugs ◽

Case Control Study ◽

Case Control ◽

University Hospital ◽

Number Of Patients ◽

Increased Risk ◽

Significant Difference ◽

Control Study

Abstract Background: Preliminary reports suggest that use of antipsychotic drugs is associated with an increased risk of venous thromboembolism (VTE), but others did not confirm these results. Objective: To evaluate the relationship between antipsychotic drugs and VTE. Design: Case-control study (EDITH) designed to investigate genetic and environmental risk factors of VTE. Setting: Brest University Hospital. Participants: 857 patients consecutively hospitalized for a documented venous thromboembolic event were included between May 2000 and May 2004. Controls were matched on age, sex and the main risk factors of venous thromboembolism (cancer, surgery, pregnancy…). Results: The mean age of patients was 67.7 year. No significant difference was found between cases and controls concerning the main characteristics, except for smocking and body mass index. Among cases, 89 (10.4%) were current users of neuroleptics compared to 35 (4.8%) among controls. Current use of neuroleptics was associated with a significant increased risk of venous thromboembolism (OR = 2.32, 95% CI: 1.55–3.48). Excluding neuroleptics used for non psychiatric disorders, and after adjustment on the main confounding factors, this association remained significant (OR = 3.48, 95% CI: 2.00–6.04). No difference was found between the different chemical categories of neuroleptics, but the number of patients in some groups had limited statistical power to demonstrate significant differences. Biological mechanisms of action have been proposed to explain this relation. Analyses are ongoing for anti-phospholipid antibodies and homocysteine. Conclusion: In this case-control study of hospitalized patients, neuroleptics use was associated with a significant increased risk of venous thromboembolism. These results are concordant with previous reports. Nevertheless, further investigations are needed to explain wich mechanisms may be involved in such association and before use of neuroleptics can be definitely considered as risk factor for venous thromboembolism.

Download Full-text